These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25581746)

  • 1. Cognitive functioning, metabolic control, and treatment type in youth with type 1 diabetes.
    Limbers CA; Emery K; Young D; Stephen M
    J Pediatr Endocrinol Metab; 2015 Mar; 28(3-4):353-5. PubMed ID: 25581746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes mellitus].
    Hasselmann C; Bonnemaison E; Faure N; Mercat I; Bouillo Pépin-Donat M; Magontier N; Chantepie A; Labarthe F
    Arch Pediatr; 2012 Jun; 19(6):593-8. PubMed ID: 22584198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of continuous subcutaneous insulin infusion on quality of life.
    Lukács A; Kiss-Tóth E; Varga B; Soós A; Takác P; Barkai L
    Int J Technol Assess Health Care; 2013 Jan; 29(1):48-52. PubMed ID: 23270655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin pump treatment; increasing prevalence, and predictors for better metabolic outcome in Danish children and adolescents with type 1 diabetes.
    Olsen B; Johannesen J; Fredheim S; Svensson J;
    Pediatr Diabetes; 2015 Jun; 16(4):256-62. PubMed ID: 25082292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy outcome and glycemic control in women with type 1 diabetes: a retrospective comparison between CSII and MDI treatment.
    Talaviya PA; Saboo BD; Joshi SR; Padhiyar JN; Chandarana HK; Shah SJ; Vyas CK; Shah AN
    Diabetes Metab Syndr; 2013; 7(2):68-71. PubMed ID: 23680243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in cognition, mood and behaviour following commencement of continuous subcutaneous insulin infusion therapy in children with type 1 diabetes mellitus: a pilot study.
    Knight S; Northam E; Donath S; Gardner A; Harkin N; Taplin C; Joy P; Cameron FJ; Ambler GR
    Diabetologia; 2009 Feb; 52(2):193-8. PubMed ID: 18987843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin pump therapy in youth with type 1 diabetes: a retrospective paired study.
    Nimri R; Weintrob N; Benzaquen H; Ofan R; Fayman G; Phillip M
    Pediatrics; 2006 Jun; 117(6):2126-31. PubMed ID: 16740856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic variability in paediatric patients with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI): a cross-sectional cohort study.
    Schreiver C; Jacoby U; Watzer B; Thomas A; Haffner D; Fischer DC
    Clin Endocrinol (Oxf); 2013 Nov; 79(5):641-7. PubMed ID: 23134485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fields of application of continuous subcutaneous insulin infusion in the treatment of diabetes and implications in the use of rapid-acting insulin analogues.
    Pitocco D; Rizzi A; Scavone G; Tanese L; Zaccardi F; Manto A; Ghirlanda G
    Minerva Endocrinol; 2013 Sep; 38(3):321-8. PubMed ID: 24126552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women.
    Mello G; Biagioni S; Ottanelli S; Nardini C; Tredici Z; Serena C; Marchi L; Mecacci F
    J Matern Fetal Neonatal Med; 2015 Feb; 28(3):276-80. PubMed ID: 24724804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life and treatment preferences in adolescents with type 1 diabetes. The VIPKIDS study.
    Cherubini V; Gesuita R; Bonfanti R; Franzese A; Frongia AP; Iafusco D; Iannilli A; Lombardo F; Rabbone I; Sabbion A; Salvatoni A; Scaramuzza A; Schiaffini R; Sulli N; Toni S; Tumini S; Mosca A; Carle F;
    Acta Diabetol; 2014 Feb; 51(1):43-51. PubMed ID: 23508374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychological impact of continuous subcutaneous insulin infusion pump therapy in non-selected newly diagnosed insulin dependent (type 1) diabetic children: evaluation after two years of therapy.
    Slijper FM; De Beaufort CE; Bruining GJ; De Visser JJ; Aarsen RS; Kicken DA; Van Strik R
    Diabete Metab; 1990; 16(4):273-7. PubMed ID: 2265733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Continuous subcutaneous insulin infusion].
    Balsa AM; Neves C; Alves M; Pereira M; Carvalho D; Medina JL
    Acta Med Port; 2011 Dec; 24 Suppl 2():147-56. PubMed ID: 22849898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is insulin pump treatment rarely used in adolescents and young adults with cystic fibrosis-related diabetes?
    Scheuing N; Badenhoop K; Borkenstein M; Konrad K; Lilienthal E; Laubner K; Naeke A; Rami-Merhar B; Thon A; Wiemann D; Holl RW;
    Pediatr Diabetes; 2015 Feb; 16(1):10-5. PubMed ID: 24984902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI).
    Bruttomesso D; Bonomo M; Costa S; Dal Pos M; Di Cianni G; Pellicano F; Vitacolonna E; Dodesini AR; Tonutti L; Lapolla A; Di Benedetto A; Torlone E;
    Diabetes Metab; 2011 Nov; 37(5):426-31. PubMed ID: 21474360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus].
    Minkina-Pedras M; Jarosz-Chobot P; Małecka-Tendera E; Deja G
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2005; 11(3):171-6. PubMed ID: 16232370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.